Professional Documents
Culture Documents
Aboy
Aboy
C. Allergic disorders
• Asthma
• Eczema
• allergies
Hypersensitivity
• refers to undesirable reactions produced by the normal immune system,
including allergies and autoimmunity
• These reactions may be damaging, uncomfortable, or occasionally fatal
Systemic Reactions
• shock and breathing difficulties
Localized Reactions
Page 12-13
Clinical manifestation
• Red oozing crusting rash
• Dry thick brownish-gred and scaly skin
• Pruritus
• Lesion are mostly found:
• Hand, foot
⁃ Back of the knees, neck, face eyelids and elbow bands
(Add missinv part)
C. ASTHMA
Is a chronic inflammatory disease of the airwys that causes airway hyper-
responsiveness, mucosal edema, and mucus production.
Predisposing Factors:
• Allergy
• Chronic Exposure to airway irritants or allergens
3 Major Signs
• Airway blockage
• Inflammation
• Airway irritability
Clinical Manifestations/Symptoms
• Cough
• Dypsnea
• Wheezing
Classification
• Mild intermittent asthma
• Mild persistent asthma
• Moderate persistent asthma
• Severe persistent asthma
RISK FACTORS
• Genes
• Race
• Lung Infection, allergies or obesity
Diagnostic Test
• Spirometry
• Peak flow
• Methacholine challenge
• Chest X- ray
• Allergy Test
Medical Management:
• Long-acting beta-agonists
• Combination inhaler
• Theophylline
• Short-acting beta-agonists
• Anticholinergics
• Oral and intravenous corticosteroids
Allergies reactions
(Pic)
PATHOPHYSIOLOGY OF AN ALLERGIC REACTION
(Pic)
Anaphylaxis
• Is an immediate life threatening systemic reaction that can occur on
exposure to a particular substances.
Causes:
• Food
• Medication
• Insect stings
Pathophysiology
(pic)
Clinical manifestation
(Pic)
Self-Administration of Epinephrine
Do’s and don’t
(Pic)
Inject the medicine into the fleshy outer portion of the thigh. Do not inject into
a vein or the buttocks.
Hold the leg firmly in place before and during the injection. You can give the
injection through clothes or on bare skin
Additional Management:
1. Antihistamine
2. Corticosteroids
3. Aminophylline
Systemic Anaphylaxis
• Due to widespread degranulation of mast cells after crosslinking of IgE
on the mast cell surface.
Severe Manifestations
• Airway obstruction and hypotension
Other signs
• Urticaria, Angioedema
Type II: Cytotoxic Reaction (Antibody-dependent)
• These allergic reactions are systemic or localized, as in allergic
dermatitis
with pic
Cytotoxic Hypersensitivity
• Antibodies involved: IgG and IgM
• Antigens: Cellular or Cell-bound
• Reactions involved antibodies directed to antigen on surface of
specific cells or tissues resulting to cytolysis (complement activation)
CLINICAL STATES
• Hemolytic Transfusion Reactions, (HTRs)
• Hemolytic Disease of the Newborn (HDN)
• Myasthenia Gravis
Erythroblastosis fetalis
• A severe hemolytic disease of a fetus or newborn caused by production
of maternal antibodies for fetal red blood cells
• Most commonly develops when an Rh+ fetus expresses an Rh antigen on its
blood that an Rh-mother
Pathophysiology
(Pic)
Myasthenia Gravis
• is a rare chronic autoimmune neuromuscular disorder that causes
weakness in the skeletal muscles, which are the muscles your body uses for
movement.
• marked by muscular weakness without atrophy, and caused by a defect in
the action of acetylcholine at neuromuscular junctions
(Pic)
Predisposing Factor
Age
• Incidence of Myasthenia Gravis occurs between ages 15-35 for women.
Gender
• Myasthenia Gravis is three times more common in women than men.
Hereditary
• A person born into family with history of certain autoimmune diseases
is at risk of developing such autoimmune disease.
Precipitating Factor
Poor environment
• Constant exposure to dust or chemical substances can weaken the immune
system of every individual that lead to infection.
Stress
• Stress can weaken the immune system
Clinical manifestation
• Expressioniess face
• Nasal timbre
• Ptosis
⁃ Diplopia
⁃ Dysphagia
⁃ Dysarthria
⁃ Dysphonia
⁃ Weakness of all extremities
Diagnostic test
• Acetylcholine Receptor Antibody
• Tensilon ® test (edrophonium chloride)
• Anti-MuSK Antibody testing
No page 57